We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Charles River Laboratories (CRL - Free Report) is expected to reveal quarterly earnings of $2.39 per share, indicating a decline of 11.2% compared to the year-ago period. Analysts forecast revenues of $1.03 billion, representing a decrease of 3.3% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Charles River metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenues- Research Models and Services' stands at $200.58 million. The estimate suggests a change of -4.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Discovery and safety assessment' will likely reach $637.52 million. The estimate points to a change of -3.9% from the year-ago quarter.
Analysts predict that the 'Revenues- Manufacturing support' will reach $192.31 million. The estimate indicates a change of +3.1% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Services' reaching $845.77 million. The estimate indicates a year-over-year change of -3.3%.
The consensus among analysts is that 'Revenues- Products' will reach $182.16 million. The estimate points to a change of -1.6% from the year-ago quarter.
According to the collective judgment of analysts, 'Operating income- Research Models and Services Non-GAAP' should come in at $48.60 million. Compared to the present estimate, the company reported $55.41 million in the same quarter last year.
The collective assessment of analysts points to an estimated 'Operating income- Discovery and safety assessment - Non-GAAP' of $156.36 million. The estimate is in contrast to the year-ago figure of $183.13 million.
Analysts forecast 'Operating income- Manufacturing support - Non-GAAP' to reach $50.39 million. The estimate is in contrast to the year-ago figure of $42.78 million.
Over the past month, Charles River shares have recorded returns of +17% versus the Zacks S&P 500 composite's -2.9% change. Based on its Zacks Rank #4 (Sell), CRL will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Charles River Laboratories (CRL - Free Report) is expected to reveal quarterly earnings of $2.39 per share, indicating a decline of 11.2% compared to the year-ago period. Analysts forecast revenues of $1.03 billion, representing a decrease of 3.3% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Charles River metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenues- Research Models and Services' stands at $200.58 million. The estimate suggests a change of -4.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Discovery and safety assessment' will likely reach $637.52 million. The estimate points to a change of -3.9% from the year-ago quarter.
Analysts predict that the 'Revenues- Manufacturing support' will reach $192.31 million. The estimate indicates a change of +3.1% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Services' reaching $845.77 million. The estimate indicates a year-over-year change of -3.3%.
The consensus among analysts is that 'Revenues- Products' will reach $182.16 million. The estimate points to a change of -1.6% from the year-ago quarter.
According to the collective judgment of analysts, 'Operating income- Research Models and Services Non-GAAP' should come in at $48.60 million. Compared to the present estimate, the company reported $55.41 million in the same quarter last year.
The collective assessment of analysts points to an estimated 'Operating income- Discovery and safety assessment - Non-GAAP' of $156.36 million. The estimate is in contrast to the year-ago figure of $183.13 million.
Analysts forecast 'Operating income- Manufacturing support - Non-GAAP' to reach $50.39 million. The estimate is in contrast to the year-ago figure of $42.78 million.
View all Key Company Metrics for Charles River here>>>
Over the past month, Charles River shares have recorded returns of +17% versus the Zacks S&P 500 composite's -2.9% change. Based on its Zacks Rank #4 (Sell), CRL will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>